Multiple Primary Malignant Tumours


  • Sajad Ahmad Salati Professor of Surgery, Unaizah College of Medicine & Medical Sciences, Qassim University, Saudi Arabia
  • Amjaad Alkhezzi Teaching Assistant, Department of Surgery, Unaizah College of Medicine & Medical Sciences, Qassim University, Saudi Arabia
  • Mohammad Ahmed Elmuttalut Assistant Professor of Community Medicine, Al-Rayan National College of Medicine, Al-Madina Al-Munawara, Saudi Arabia
  • Muhammad Munir Memon Assistant Professor of Surgery, Qassim College of Medicine, Qassim University, Saudi Arabia
  • Mushhood Memon Resident Internal Medicine, St. Barnabas Hospital, Bronx, NY, USA



Multiple primary malignant tumours, synchronous, metachronous, prognosis, survival, hormones


Two or more histologically distinct malignancies in one individual are termed as multiple primary malignant tumours (MPMT). The incidence of these cases has been rising over the past few decades, primarily due to improved methods for cancer screening, diagnosis, treatment, and follow-up. They can show up as metachronous lesions later on or synchronously with the index malignancy. The precise aetiology is still unknown; however, a number of epidemiological variables have been proposed as potential risk factors. Modern imaging techniques are very helpful in the diagnosing process. Physician awareness is essential in order to raise suspicions about the potential for MPMT and to conduct appropriate investigations. There are currently no universal protocols based on evidence; instead, management is empirical and dependent on the judgments made by interdisciplinary teams.


Billroth T. Pathology and therapeutics, in fifty lectures. 1871. Clin Orthop Relat Res 2003; (408): 4-11. DOI:

Han Y, Shao N, Xi X, Hao X. Use of microwave ablation in the treatment of patients with multiple primary malignant tumors. Thorac Cancer 2017; 8(4): 365-371. DOI:

Zhang L, Feng L, Cong H, Yu Z, Wang H, Dong Y, Wang J. Multiple primary malignant neoplasms: A case report and literature review. Oncol Lett 2019; 18(4): 4210-4220. DOI:

Warren S, Gates O. Multiple Primary Malignant Tumors: A Survey of the Literature and Statistical Study. American Journal of Cancer 1932; 16: 1358-1414.

Shah SA, Riaz U, Zahoor I, Jalil A, Zubair M. Carcinoma multiplex. J Coll Physicians Surg Pak 2013; 23(4): 290-2.

Amer MH. Multiple neoplasms, single primaries, and patient survival. Cancer Manag Res 2014; 6: 119-34. DOI:

Demandante CG, Troyer DA, Miles TP. Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol 2003; 26(1): 79-83. DOI:

Babacan NA, Aksoy S, Cetin B, Ozdemir NY, Benekli M, Uyeturk U, Ali Kaplan M, Kos T, Karaca H, Oksuzoglu B, Zengin N, Buyukberber S. Multiple primary malignant neoplasms: multi-center results from Turkey. J BUON 2012; 17(4): 770-5.

Xu LL, Gu KS. Clinical retrospective analysis of cases with multiple primary malignant neoplasms. Genet Mol Res 2014; 13(4): 9271-84. DOI:

Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12(1): 20-37. DOI:

Weir HK, Johnson CJ, Thompson TD. The effect of multiple primary rules on population-based cancer survival. Cancer Causes Control 2013; 24(6): 1231-42. DOI:

Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 2007; 16(3): 566-71. DOI:

Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open 2017; 2(2): e000172. DOI:

Soerjomataram I, Coebergh JW. Epidemiology of multiple primary cancers. Methods Mol Biol 2009; 471: 85-105. DOI:

Cybulski C, Nazarali S, Narod SA. Multiple primary cancers as a guide to heritability. Int J Cancer 2014; 135(8): 1756-63. DOI:

Kang GH, Kim CJ, Kim WH, Kang YK, Kim HO, Kim YI. Genetic evidence for the multicentric origin of synchronous multiple gastric carcinoma. Lab Invest 1997; 76(3): 407-17.

Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, Gallinger B, Naumer A, Kohlmann W, Novokmet A, Tabori U, Tijerin M, Greer ML, Finlay JL, Schiffman JD, Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol 2016; 17(9): 1295-305. DOI:

Pang JT, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Eur J Cancer 1994; 30A(13): 1961-8. DOI:

Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Mulligan LM, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996; 276(19): 1575-9. DOI:

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci USA 2014; 111(39): 14205-10. DOI:

Albright F, Teerlink C, Werner TL, Cannon-Albright LA. Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site. BMC Cancer 2012; 12: 138. DOI:

Morita M, Kuwano H, Baba H, Taketomi A, Kohnoe S, Tomoda H, Araki K, Saeki H, Kitamura K, Sugimachi K. Multifocal occurrence of gastric carcinoma in patients with a family history of gastric carcinoma. Cancer 1998; 83(7): 1307-11.<1307::AID-CNCR6>3.0.CO;2-F DOI:<1307::AID-CNCR6>3.0.CO;2-F

Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21(3): 427-33. DOI:

Ricceri F, Fasanelli F, Giraudo MT, Sieri S, Tumino R, Mattiello A, Vagliano L, Masala G, Quirós JR, Travier N, Sánchez MJ, Larranaga N, Chirlaque MD, Ardanaz E, Tjonneland A, Olsen A, Overvad K, Chang-Claude J, Kaaks R, Boeing H, Clavel-Chapelon F, Kvaskoff M, Dossus L, Trichopoulou A, Benetou V, Adarakis G, Bueno-de-Mesquita HB, Peeters PH, Sund M, Andersson A, Borgquist S, Butt S, Weiderpass E, Skeie G, Khaw KT, Travis RC, Rinaldi S, Romieu I, Gunter M, Kadi M, Riboli E, Vineis P, Sacerdote C. Risk of second primary malignancies in women with breast cancer: Results from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 2015; 137(4): 940-8. DOI:

Neugut AI, Murray TI, Lee WC, Robinson E. The association of breast cancer and colorectal cancer in men. An analysis of surveillance, epidemiology, and end results program data. Cancer 1991; 68(9): 2069-73.<2069::AID-CNCR2820680938>3.0.CO;2-M DOI:<2069::AID-CNCR2820680938>3.0.CO;2-M

Day AT, Tang L, Karam-Hage M, Fakhry C. Tobacco Treatment Programs at National Cancer Institute-designated Cancer Centers: A Systematic Review and Online Audit. Am J Clin Oncol 2019; 42(4): 407-410. DOI:

Tabuchi T, Ito Y, Ioka A, Nakayama T, Miyashiro I, Tsukuma H. Tobacco smoking and the risk of subsequent primary cancer among cancer survivors: a retrospective cohort study. Ann Oncol 2013; 24(10): 2699-2704. DOI:

Romaszko-Wojtowicz A, Buciński A, Doboszyńska A. Impact of smoking on multiple primary cancers survival: a retrospective analysis. Clin Exp Med 2018; 18(3): 391-397. DOI:

Fitzpatrick P, Bhardwaj N, Masalkhi M, Lyons A, Frazer K, McCann A, Syed S, Niranjan V, Kelleher CC, Brennan S, Kavanagh P, Fox P. Provision of smoking cessation support for patients following a diagnosis of cancer in Ireland. Prev Med Rep 2023; 32: 102158. DOI:

Hsu WL, Chien YC, Chiang CJ, Yang HI, Lou PJ, Wang CP, Yu KJ, You SL, Wang LY, Chen SY, Yang CS, Chen CJ. Lifetime risk of distinct upper aerodigestive tract cancers and consumption of alcohol, betel and cigarette. Int J Cancer 2014; 135(6): 1480-6. DOI:

Day GL, Blot WJ, Shore RE, McLaughlin JK, Austin DF, Greenberg RS, Liff JM, Preston-Martin S, Sarkar S, Schoenberg JB, et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 1994; 86(2): 131-7. DOI:

Druesne-Pecollo N, Keita Y, Touvier M, Chan DS, Norat T, Hercberg S, Latino-Martel P. Alcohol drinking and second primary cancer risk in patients with upper aerodigestive tract cancers: a systematic review and meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2014; 23(2): 324-31. DOI:

Kmet LM, Cook LS, Weiss NS, Schwartz SM, White E. Risk factors for colorectal cancer following breast cancer. Breast Cancer Res Treat 2003; 79(2): 143-7. DOI:

Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM. Breast cancer risk factors and second primary malignancies among women with breast cancer. Breast Cancer Res Treat 2007; 105(2): 195-207. DOI:

Jung SY, Kim YA, Jo M, Park SM, Won YJ, Ghang H, Kong SY, Jung KW, Lee ES. Prediagnosis obesity and secondary primary cancer risk in female cancer survivors: A national cohort study. Cancer Med 2019; 8(2): 824-838. DOI:

Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010; 61: 301-16. DOI:

Messier KP, Serre ML. Lung and stomach cancer associations with groundwater radon in North Carolina, USA. Int J Epidemiol 2017; 46(2): 676-685. DOI:

Bräuner EV, Loft S, Sørensen M, Jensen A, Andersen CE, Ulbak K, Hertel O, Pedersen C, Tjønneland A, Krüger Kjær S, Raaschou-Nielsen O. Residential Radon Exposure and Skin Cancer Incidence in a Prospective Danish Cohort. PLoS One 2015; 10(8): e0135642. DOI:

Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119(12): 2764-7. DOI:

Lacouture ME, O'Reilly K, Rosen N, Solit DB. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J Clin Oncol 2012; 30(3): 329-30. DOI:

Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R. Successes and Challenges of PARP Inhibitors in Cancer Therapy. Front Oncol 2015; 5: 222. DOI:

Dohner VA, Beegle RG, Miller WT. Asbestos exposure and multiple primary tumors. Am Rev Respir Dis 1975; 112(2): 181-99.

Fischbein A, Luo JC, Pinkston GR. Asbestosis, laryngeal carcinoma, and malignant peritoneal mesothelioma in an insulation worker. Br J Ind Med 1991; 48(5): 338-41. DOI:

Attanoos RL, Thomas DH, Gibbs AR. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals. Histopathology 2003; 43(4): 387-92. DOI:

Kollias J, Ellis IO, Elston CW, Blamey RW. Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg 2001; 25(9): 1117-24. DOI:

Friedrich RE. Primary and second primary cancer in 649 patients with malignancies of the maxillofacial region. Anticancer Res 2007; 27(4A): 1805-18.

Aziz TM, Saad RA, Glasser J, Jilaihawi AN, Prakash D. The management of second primary lung cancers. A single centre experience in 15 years. Eur J Cardiothorac Surg 2002; 21(3): 527-33. DOI:

Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46(5): 752-7.

Miyazaki T, Sohda M, Higuchi T, Tanaka N, Suzuki S, Sakai M, Yokobori T, Nakajima M, Fukuchi M, Tsushima Y, Kato H, Kuwano H. Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer. Anticancer Res 2014; 34(1): 283-7.




How to Cite

Salati, S. A., Alkhezzi, A., Elmuttalut, M. A., Memon, M. M., & Memon, M. (2023). Multiple Primary Malignant Tumours. Journal of Analytical Oncology, 12, 77–83.




Most read articles by the same author(s)